Alligator announces evaluation and option agreement covering RUBY™ antibody format
Lund, Sweden – 2 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Alligator has entered into ...
Exercise price determined for the exercise of warrants series TO 13 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience provides highlights from R&D event 2025
Lund, Sweden – 20 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Alligator Bioscience announces upcoming presentation of REACtiVe-2 Phase 1 data at ESMO Congress 2025
Lund, Sweden – 25 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer
Lund, Sweden – 14 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...
Alligator to present 24-month OPTIMIZE-1 data at ESMO GI 2025
Lund, Sweden, 1 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical- ...
Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab
Lund, Sweden, 17 June 2025 — Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-d ...
Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer
Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting
Lund, Sweden, 3 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that biomarker data from its OPTIMIZE-1 cli ...